US National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with US DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Pluri Inc. will collaborate with the US Department of Defense’s Armed Forces Radiobiology Research Institute/Uniformed Services University of Health Sciences to further advance the development of its PLX-R18 cell therapy as a potential novel treatment for Hematopoietic Acute Radiation Syndrome.